To accomplish this goal, it was essential to purchase state of the art mass spectrometry instrumentation. The rationale for the proposed work is that, once the optimal method parameters are established using advanced mass spectrometry and relevant oncoproteomic technologies to facilitate method development, to investigate a solid tumor of interest, homogeneous histological tumor/tissue cells (i.e., tumor proper, stroma, etc) can be effectively studied for biomarkers, drug targets, and pathways, with the goal of improving our basic understanding of a given disease-state.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC011226-01
Application #
7966254
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
2009
Total Cost
$86,015
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Ye, Xiaoying; Luke, Brian T; Johann Jr, Donald J et al. (2010) Optimized method for computing (18)O/(16)O ratios of differentially stable-isotope labeled peptides in the context of postdigestion (18)O exchange/labeling. Anal Chem 82:5878-86
Johann Jr, Donald J; Wei, Bih-Rong; Prieto, DaRue A et al. (2010) Combined blood/tissue analysis for cancer biomarker discovery: application to renal cell carcinoma. Anal Chem 82:1584-8
Johann, Donald J; Rodriguez-Canales, Jaime; Mukherjee, Sumana et al. (2009) Approaching solid tumor heterogeneity on a cellular basis by tissue proteomics using laser capture microdissection and biological mass spectrometry. J Proteome Res 8:2310-8
Mbeunkui, Flaubert; Johann Jr, Donald J (2009) Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother Pharmacol 63:571-82